Olema Oncology Hoping to Avoid Past Pharma Mistakes With Complete Estrogen Receptor Antagonist
The company's lead compound adds estrogen receptor inhibition on top of degradation to completely shut down breast cancer-promoting activity.
Results were mixed for SERDs and SERMs in advanced breast cancer, but benefits for patients with ESR1 resistance mutations stood out.
Sanofi Ends Development of Breast Cancer Drug Amcenestrant
The company is ending all clinical trials of the investigational SERD after a Phase III study failed to meet a prespecified endpoint in an interim analysis.
Regeneron to Buy Out Libtayo From Sanofi
The transaction slated to close in Q3 will give Regeneron exclusive worldwide development, commercialization, and manufacturing rights.
In Brief This Week: Cullinan Oncology, Aileron Therapeutics, Sanofi, Exscientia
News items for the week of Jan. 3, 2022.